Group Profile
HOME > ABOUT US > Group Profile

Saikesaisi Holding Group is a comprehensive enterprise group that focuses on pharmaceuticals as the mainstay industry and relies on the innovation of science and technology (talent) and sustainable development. Headquartered in No. 2222, Kaifeng Road, High-tech Zone, Jinan City, Shandong Province, the Group is principally engaged in the research and development, production and sales of new special drugs, medical devices, biomedical materials and plant interventional treatment products, and hydrogen energy and new materials. The group's assets amount to 1.15 billion yuan and its annual sales income reaches 1.2 billion yuan. The group has more than 600 employees, including more than 100 R&D technicians (PhD or MS). At present, the group is mainly involved in the four major sectors of biomedicine, medical services, hydrogen energy and investment.

First, the biomedical sector

1. Shandong Saikesaisi Biotechnology Co., Ltd. is located in the Biomedical Industrial Park in the High-tech Zone of Jinan City. It was established in 2003 with a registered capital of 200 million yuan and covers an area of approximately 21,500 square meters. Currently, it has 400 million yuan in fixed assets and more than 280 employees. It is a national high-tech enterprise engaged in research, development, production, sales, and service of medical devices. In order to expand the R&D and production scale, the company started investing in the medical equipment production base in Jinan Yaogu Industrial Park in eastern Jinan in 2016. The total land area for the construction project is approximately 140 mu, and the total construction area is over 80,000 square meters. Up to 540 million yuan. The first-phase construction project has a construction area of more than 50,000 square meters and a total investment of 276 million yuan. The company has a solid and innovative R&D team, with more than 60 R&D personnel including postdoctoral, doctoral, and graduate students. The company owns more than 20 national invention patents and participates in the formulation of 4 industry standards. The leader of the team, Zhao Chengru, has more than 30 years of experience in the development and management of medical device products. He has participated in national, provincial, and municipal research projects on multiple occasions. His R&D team was identified in 2015 as the “Hai Right Talent Innovation Team”, 2017 Selected for "Spring City Industry Leader Talent Support Program" (innovation team). The company has passed the BSI accredited ISO13485 quality management system and intellectual property management system certification. It has the title of “National Intellectual Property Advantage Enterprise” and “Shandong Province Intellectual Property Demonstration Enterprise” and has built the “Shandong Institute of Implantable Materials Engineering and Technology Research Center”. And the “Shandong Provincial Enterprise Technology Center” two provincial innovation platforms, in 2017 set up a city postdoctoral innovation practice workstation.
The company aims at the frontier areas of the world, closely follows the development pace of high-end medical devices at home and abroad, and relies on the two innovation platforms of “Shandong Province In vivo Implanted Materials Engineering Technology Research Center” and “Shandong Enterprise Technology Center”. Leading level of more than 50 high-tech products. At present, the company has 12 products listed on the market, among which, surgical anti-blocking liquid was identified as “national key new product” by the Ministry of Science and Technology, and “transient” compound microporous polysaccharide hemostatic powder is the world’s second after Arista, and was first introduced in China. Starch hemostatic products; "Yawei" non-adhesive liquid embolization materials are the second domestic product after ONYX, and domestic exclusive products; absorbable dura closure medical glue is the first domestic CFDA-approved innovative medical treatment. The device specially approves the "Green Passage" and domestic first products.
2. Shandong Saikesaisi Pharmaceutical Sales Co., Ltd. The company is mainly engaged in the sales of new special drugs, promotion of pharmaceuticals, etc., and has maintained long-term friendly cooperative relations with Shanghai Pharmaceutical Group and China Resources Group, and has continued to cooperate with large-scale commercial distribution companies such as Sinopharm, China Resources Medicine, Jiuzhou TongPharma, and Shanghai Pharmaceuticals. Business dealings. Business involves the cardiovascular and cerebrovascular category, nutrition, antibiotics, pediatrics and other products. Among them, calcium dibutyrocycline adenosine for injection has been awarded the title of “Shanghai Famous Brand Product”, which solves the problem of 5 million cardiovascular patients each year. At present, the company's sales network covers the entire country, with 23 branches and 31 offices throughout the country. The business covers 30 provinces, cities and autonomous regions across the country.
Second, the medical service sector
1. Qilu Hemodialysis Service Management Co., Ltd. The company is affiliated to Shandong Saikesaisi Holding Group, established in November 2014, with a paid-up capital of RMB 180 million. Based on the high-end health service industry, it targets the domestic potential market of RMB 100 billion and strives to build the leading hemodialysis chain group in the country. Become the first brand in domestic hemodialysis industry.
Since its inception, the company has invested and established 10 independent centers in Guangdong, Shanxi, and Fujian provinces; Shandong province has just received two independent centers. At the same time, it reached a strategic cooperation relationship with 25 hospitals. The number of patients served exceeds 2,000, and clinical hemodialysis is conducted 500,000 times. In 2017, the output value exceeded 100 million yuan.
In response to the national “health poverty alleviation” call, with the approval of the Shandong Provincial Department of Civil Affairs, the “Yandong Mingqilu Hemodialysis Public Welfare Foundation” was initiated. The initial fundraising amount was 10 million, and the rolling fund raising target was 100 million yuan. All of them will be used. For the treatment of uremia patients with difficulty in living, on the basis of national medical insurance, free uremic patients are treated free of charge.
Qilu hemodialysis medical care team is led by famous experts and professors at home and abroad, the industry association chairperson, dozens of middle-level and above nephrology specialists, more than one hundred senior nursing specialists, and professionals who have been continuously trained in reserve. Established a platform for academic exchange and interaction with more than a dozen tertiary general hospitals, opened a green channel for the referral of critically ill patients, and created an arteriovenous fistula surgery center and expert consultation and training base. The support of all-round three-dimensional medical care technology supports escort for clinical safety and patient health.
2. Shandong Medical Yuan Multi-function Stem Cell Bioengineering Co., Ltd. The company was incorporated on December 25, 2013 and its registered address is located in Jinan High-tech Zone Comprehensive Bonded Zone. Its main business scope is biological genetic engineering technology research and development, technical services, technical consultation, and technology transfer; research and development and sales of cellular products; goods and technology The import and export business.
The company cooperates with the Shandong Provincial Institute of Drug Research and is mainly responsible for the promotion of the isolation, extraction, preparation, and preservation of placenta derived stem cells from the pluripotent stem cell bank in Shandong Province. The Shandong Provincial Institute of Pharmaceutical Research is a public institution funded and organized by the Shandong Academy of Medical Sciences. It is responsible for the construction and operation of the Shandong Province's pluripotent stem cell bank. Shandong Province's pluripotent stem cell bank was jointly constructed by the Shandong Academy of Medical Sciences and the National Stem Cell Engineering Technology Research Center. The only one in Shandong Province that has been approved by the former Shandong Provincial Department of Health to carry out stem cell storage for stem cells other than cord blood stem cells.
The Shandong Province pluripotent stem cell bank is located in the GMP laboratory building of the Shandong Provincial Institute of Pharmaceutical Research (Shandong Provincial Institute of Medicine) in Zhangqiu City. It is a site for stem cell extraction, separation, storage, and research. The project has invested more than 50 million yuan and the building area is more than 2,500 square meters. In accordance with national standards for the construction of biological laboratories, the company will establish and implement the “GMP for pharmaceutical production” (GMP) and the “Standard for Clean Construction and Acceptance” of the national standard. The construction will be carried out by companies with construction qualifications and construction experience. The construction materials meet the above requirements. .
Third, the new energy sector
Shandong Saikesaisi Hydrogen Energy Co., Ltd. was restructured from the Jinan Institute of Applied Chemicals and is the first domestic unit to develop a PEM hydrogen generator. Through the hydrogen production technology of PEM electrolyzed water, four generations of hydrogen generators have been developed, which are cleaner, safer, and more efficient than traditional hydrogen production processes using alkaline solutions. The listed products have filled the blank of domestic large-scale hydrogen production equipment for PEM technology, and have obtained various honors and certificates such as BCEIA Gold Award, European CE Certification, and national key new products, and have been exported to more than 20 countries including the United States, the United Kingdom, South Korea, and Japan.
Shandong Saikesaisi Hydrogen Energy Co., Ltd. is affiliated to Shandong Saikesaisi Holding Group. The company is a multi-disciplinary high-tech personnel and is a highly innovative and innovative team. The chief technical leader is the earliest Chinese expert who developed SPE electrode technology. He has more than 20 years of relevant R&D experience and has developed four generations of this technology's hydrogen generator products, all of which have been patented. This technology fills the domestic gap and replaces the traditional hydrogen production process.
Fourth, investment section
Duoying Investment Management Co., Ltd. (abbreviated as "Multiple Capital"). The company was established in 2011 and owns multiple investment brands such as Duo Ying Investment, Duo Run Investment, and Zhongxing Prime Investment. Currently, it manages several specialized equity investment funds involving energy conservation and environmental protection, new materials, modern service industries, and cultural industries. , The scale of more than 2 billion yuan; management industry investment funds, special funds, etc. more than 10 billion yuan.
More than surplus capital's Shandong Duoying Equity Investment Management Co., Ltd. (abbreviated as “Shandong Duo Ying”) is a professional investment company established by Shandong Venture Capital in a venture capital and equity investment management business and is a securities investment company in China. Special member of the fund association, director unit of Shandong Provincial Equity and Venture Capital Association. Shandong Duoying has successively managed equity investment funds such as Tianjin Mutual Fund, Mutual Energy Saving & Environmental Protection Fund, and a management scale of more than 800 million yuan. Shandong Duoyin is a venture capital project for emerging industries. It is a provincial-level counterpart fund management agency for Shandong Province. It is responsible for the management of provincial-level equity funds; it is a provincial equity investment guidance fund for Shandong Province and equity investment in Yantai, Zaozhuang and other cities. Guided funds provide related consulting services. The company has a professional and highly qualified staff team. The management team is rich in talent, advanced in philosophy and experienced in the development of the industry and the company has a keen insight into the direction of development, the development of the core investment team has many years of experience in venture capital.
Saikesaisi Holding Group will take the national strategy of implementing the new and old kinetic energy conversion project as its guideline, further increase scientific and technological innovation, accelerate the implementation of industrial transformation and upgrading, continuously surpass the world advanced level, and strive to become the No. 1 in the field of domestic absorbable medical sealants. Leading the world, and strive for the successful listing of the bio-pharmaceuticals board as soon as possible. We will uphold the spirit of the party's Nineteenth Congress, thoroughly implement Xi Jinping’s socialist ideology with Chinese characteristics in the new era, work hard, advance forward, and create a brilliant future for Cyckes! To make greater contributions to the development of the city, the province, and our national industry!